PMID: 8591712Sep 1, 1995Paper

Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients

Diabetes Research and Clinical Practice
A ZhangI De Leeuw

Abstract

The effects of pravastatin on plasma lipid levels, in vitro oxidizability of the non-HDL fraction, metabolic control, urinary albumin excretion, and four serum enzymes (SGPT, SGOT, GT and CPK) were studied in 20 insulin-dependent diabetic patients (IDDM) with incipient nephropathy. The patients were divided into two groups and the study was carried out by a crossover design. After 12 weeks pravastatin treatment (20 mg daily), plasma cholesterol, LDL-cholesterol and apolipoprotein B (Apo B) decreased by 22, 19 and 15%, respectively. The thiobarbituric acid reactive substances (TBARS) formation and the oxidation lagtime of the non-HDL fraction during the in vitro incubation with copper were not changed before and after treatment. The HbA1c and blood glucose levels, urinary albumin excretion, SGOT, SGPT and GT were not influenced by pravastatin treatment. CPK activity was elevated after 12 weeks of pravastatin treatment, and this elevation persisted even after the 12 weeks placebo period. So, pravastatin could be used as an effective drug for IDDM patients with incipient nephropathy, but close monitoring of the CPK activity is recommended.

References

Apr 1, 1976·Biochemical Medicine·K Yagi
May 1, 1991·Metabolism: Clinical and Experimental·A S DobsS Margolis
Jan 1, 1991·European Journal of Clinical Pharmacology·G PaolissoF D'Onofrio
Nov 1, 1987·Kidney International·J R Diamond, M J Karnovsky
Feb 9, 1984·The New England Journal of Medicine·C E Mogensen
Jun 1, 1994·Kidney International·D C WheelerJ D Williams
Jun 10, 1993·The New England Journal of Medicine·D M Nathan

❮ Previous
Next ❯

Citations

Dec 1, 2005·Current Diabetes Reports·Mark E Cooper, Karin A M Jandeleit-Dahm
Jul 3, 1998·Diabetes Research and Clinical Practice·O González-AlbarránR García Robles
Dec 12, 2001·Journal of the American College of Cardiology·L M RuilopeT F Luscher
May 19, 2001·Journal of Diabetes and Its Complications·L F FriedT J Orchard
May 1, 1997·Clinical and Experimental Pharmacology & Physiology·R Scott
Mar 9, 2005·Kidney International. Supplement·Hung-Chun ChenYung-Hsiung Lai
Dec 13, 2005·Kidney International. Supplement·Aleix Cases, Elisabet Coll
Mar 16, 2005·Pharmacotherapy·Alan J ZillichUNKNOWN Nephrology Practice and research networks of the American college of Clinical Pharmacy
Jan 19, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Zhenhong ZhangGengxin Zhang
Jan 24, 2012·Journal of Clinical Lipidology·Jonathan R MurrowArshed A Quyyumi
Aug 9, 2006·European Journal of Clinical Investigation·O M SteinmetzU O Wenzel
Aug 26, 1998·The Tohoku Journal of Experimental Medicine·T SatoM Fukuda
Jan 31, 2006·Diabetes Care·Merlin C ThomasPer-Henrik Groop
Jun 26, 2001·Kidney International·N ChaturvediJ H Fuller
Jul 21, 1999·Kidney International. Supplement·K Jandeleit-DahmM E Cooper
Jun 1, 2014·The Cochrane Database of Systematic Reviews·Suetonia C PalmerGiovanni F M Strippoli
May 15, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Tuula JanatuinenOlli T Raitakari
Jun 11, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·A PalomäkiT Solakivi
Jun 10, 2006·Journal of the American Society of Nephrology : JASN·Sabrina SandhuMarcello Tonelli
Jul 5, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Sara TehraniGun Jörneskog
Aug 2, 2019·Therapeutic Advances in Chronic Disease·Angelo ZinelluArduino A Mangoni
Apr 28, 2004·Clinical Therapeutics·Sarkis B BaghdasarianByron J Hoogwerf
Jan 3, 2001·Kidney International·L F FriedB L Kasiske

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

© 2021 Meta ULC. All rights reserved